China Pharma Holdings Q2 2014 revenue decreases by 24 percent to $6.
We renewed our ‘National High-Tech Enterprise’ position from the PRC government in the third quarter of 2013. With this designation, december 31 for the years ending, 2014, 2015 and 2016, we will continue steadily to like a preferential tax price of 15 percent which is normally notably less than the statutory tax rate of 25 percent. Net loss was $8.6 million or $0.20 per diluted and basic share in the second quarter of 2014, in comparison to $4.5 million, or $0.10 per diluted and basic share in the same period in 2013. The upsurge in net reduction was primarily because of the decrease in sales, the increase in bad debt expenditure and R&D expense recognized for the three months ended June 30, 2014.Related StoriesVISERA 4K UHD endoscopy system gives surgeons 4x resolutionJumping genes: a marker for early cancer tumor diagnosis? An interview with Dr KazazianRapid, award earning diagnostic testing to be provided at MEDICA’Until it could be clearly demonstrated that correcting anemia boosts outcomes, I think that working to appropriate and preserve the organic hemoglobin in a patient’s blood prior to surgery is a practicable and safe choice,’ Dr.